Literature DB >> 2254459

Role of intact cardiac nerves and reflex mechanisms in desensitization to catecholamines in conscious dogs.

J Nejima1, N Uemura, D E Vatner, C J Homcy, T H Hintze, S F Vatner.   

Abstract

To study chronic catecholamine desensitization, mini-osmotic pumps were implanted subcutaneously to deliver NE, (0.5 micrograms/kg/min) or saline over 3-4 wk in dogs instrumented with left ventricular (LV) pressure gauges and arterial and left atrial pressure catheters. An acute challenge to NE (0.4 micrograms/kg/min) in intact, conscious dogs increased LV dP/dt by 1,531 +/- 208 mmHg/s before NE pumps, and by a similar amount, 1,340 +/- 166 mmHg/s, 3-4 wk after NE pumps. In contrast, an acute challenge to isoproterenol (ISO, 0.4 micrograms/kg/min) increased LV dP/dt by 5,344 +/- 532 mmHg/s before NE pumps, and significantly less (P less than 0.05; 2,425 +/- 175 mmHg/s) after NE pumps. In the presence of ganglionic and alpha 1-adrenergic blockades, NE (0.4 micrograms/kg/min) increased LV dP/dt by 3,656 +/- 468 mmHg/s before NE pumps and significantly less (P less than 0.01; 1,459 +/- 200 mmHg/s) after NE pumps. Confirming this, an acute challenge to NE (0.4 micrograms/kg/min) in dogs with arterial baroreceptor denervation increased LV dP/dt by 3,732 +/- 896 mmHg/s before NE pumps, and significantly less (P less than 0.05, 1,725 +/- 408 mmHg/s) after NE pumps. In addition, in cardiac denervated dogs, NE (0.4 micrograms/kg/min) increased LV dP/dt by 9,901 +/- 1,404 mmHg/s before NE pumps and significantly less (P less than 0.01, 2,690 +/- 306 mmHg/s) after NE pumps. Desensitization of heart rate responses to NE challenge was also more apparent in the absence of reflex mechanisms. Thus, neural reflex mechanisms play a major role in physiological expression of cardiac desensitization to catecholamines in conscious dogs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2254459      PMCID: PMC329843          DOI: 10.1172/JCI114941

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  Further observations of certain responses of tolerant and control animals to massive doses of epinephrine.

Authors:  H E ESSEX
Journal:  Am J Physiol       Date:  1952-10

2.  Studies on physiologic effects of large doses of epinephrine.

Authors:  I M VIGRAN; H E ESSEX
Journal:  Am J Physiol       Date:  1950-07-01

3.  A different desensitization pattern of cardiac beta-adrenoceptor subtypes by prolonged in vivo infusion of isoprenaline.

Authors:  C Nanoff; M Freissmuth; E Tuisl; W Schütz
Journal:  J Cardiovasc Pharmacol       Date:  1989-02       Impact factor: 3.105

Review 4.  Agonist-induced desensitization of the beta-adrenergic receptor-linked adenylate cyclase.

Authors:  T K Harden
Journal:  Pharmacol Rev       Date:  1983-03       Impact factor: 25.468

5.  Evidence for uncoupling of the beta receptor-adenylate cyclase complex.

Authors:  J D Marsh; W H Barry; E J Neer; R W Alexander; T W Smith
Journal:  Circ Res       Date:  1980-10       Impact factor: 17.367

6.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

Authors:  M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson
Journal:  N Engl J Med       Date:  1982-07-22       Impact factor: 91.245

7.  Selective desensitization of cardiac beta adrenoceptors by prolonged in vivo infusion of catecholamines in rats.

Authors:  H Y Chang; R M Klein; G Kunos
Journal:  J Pharmacol Exp Ther       Date:  1982-06       Impact factor: 4.030

8.  Chronic norepinephrine infusion and adrenergic function of hypertrophied hearts.

Authors:  F M Siri
Journal:  Am J Physiol       Date:  1985-04

9.  Effects of insulin on experimental catecholamine cardiomyopathy.

Authors:  S E Downing; J C Lee
Journal:  Am J Pathol       Date:  1978-11       Impact factor: 4.307

Review 10.  Increased plasma catecholamine levels in patients with symptomatic mitral valve prolapse.

Authors:  A Pasternac; J F Tubau; P E Puddu; R B Król; J de Champlain
Journal:  Am J Med       Date:  1982-12       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.